Lyell Immunopharma Inc.

LYEL | NASDAQ

Price Alert Chart Builder DCF Calculator

$11.12

+$0.19 (+1.74%)

Sep 22, 2026, 2:42 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.74%

(1D)

Rating

Updated: Sep 18, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $272.49M

1D Range

10.95 11.19

52W Range

10.46 45

Valuation (TTM)

PE -0.93

PB 1.15

EV/EBITDA -0.51

Valuation (NTM)

Forward PE N/A

Forward PEG -0.14

Price Target $42.67

Cash Flow

FCF Yield -64.4%

SBC Adj. FCF Yield -79.2%

SBC Impact -23.0%

Margins

Gross Margin -8537.0%

Operating Margin -542522.2%

FCF Margin -639148.2%

Growth (CAGR)

Revenue 3Y | 5Y -91.8% | -68.3%

Dil EPS 3Y | 5Y -99.1% | -67.2%

FCF 3Y | 5Y -4.0% | 2.0%

Returns

ROA -79.9%

ROE -91.6%

ROIC -70.8%

Financial Health

Net Cash

$167.17M

Current Ratio 5.36

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The com...

Sector Healthcare

Industry Biotechnology

Employees 161

IPO Date Jun 16, 2021

Website www.lyell.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 10, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$45

Upside

+304.68%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞